Table 2 Correlation between HER2 gene amplification status and clinicopathological parameters

Total

n = 169

n = 24 (14.2%)

n = 145 (85.8%)

Age at diagnosis

0.660

  ≥ 60 years

88

14 (15.9)

74 (84.1)

  < 60 years

81

10 (12.3)

71 (87.7)

Gender

1.000

Male

138

20 (14.5)

118 (85.5)

Female

31

4 (12.9)

27 (87.1)

Tumor differentiation

0.346^a

Well

17

1 (5.9)

16 (94.1)

Moderate

91

12 (13.2)

79 (86.8)

Poor

54

9 (16.7)

45 (83.3)

Basaloid

6

2 (33.3)

4 (66.7)

Spindle cell

1

0 (0.0)

1 (100.0)

pT status

0.183

pT1

27

7 (25.9)

20 (74.1)

pT2

21

2 (9.5)

19 (90.5)

pT3 + T4

121

15 (12.4)

106 (87.6)

pN status

0.765

pN0

81

12 (14.8)

69 (85.2)

pN1

48

8 (16.7)

40 (83.3)

pN2

26

2 (7.7)

24 (92.3)

pN3

14

2 (14.3)

12 (85.7)

pM status

NA

pM0

169

24 (14.2)

145 (85.8)

pM1

0

0 (0.0)

0 (0.0)

pTNM stage

0.858

I

22

4 (18.2)

18 (81.8)

II

65

10 (15.4)

55 (84.6)

III

66

8 (12.1)

58 (87.9)

IV

16

2 (12.5)

14 (87.5)